Century Therapeutics (IPSC) financial statements
Century Therapeutics reported revenue of $109M in fiscal 2025, up 175.9% a year over 3 years.
Net income was -$10M.
Free cash flow was -$105M.
The diluted share count rose 1057% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Century Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $5M | $2M | $7M | $109M |
| Research and development | $40M | $76M | $97M | $93M | $107M | $96M |
| Selling, general and admin | $9M | $19M | $32M | $35M | $33M | $24M |
| Operating income | -$54M | -$95M | -$134M | -$147M | -$138M | -$17M |
| Interest expense | $381,000 | $1M | $1M | $540,000 | — | — |
| Pre-tax income | -$54M | -$96M | -$131M | -$135M | -$125M | -$10M |
| Income tax | — | $43,000 | $91,000 | $2M | $2M | -$68,000 |
| Net income | -$54M | -$96M | -$131M | -$137M | -$127M | -$10M |
| EPS (diluted) | -$7.16 | -$2.96 | -$2.96 | -$2.30 | -$1.61 | -$0.14 |
| Diluted shares | 7M | 32M | 32M | 59M | 79M | 87M |
| Operating margin | — | — | -2574.2% | -6556.9% | -2096.5% | -15.8% |
| Net margin | — | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
Balance sheet
Fiscal years, from Century Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $76M | $223M | $315M | $173M | $189M | $117M |
| Total current assets | $79M | $228M | $320M | $177M | $194M | $121M |
| Property, plant and equipment | $15M | $58M | $83M | $72M | $62M | $50M |
| Total assets | $107M | $437M | $487M | $361M | $353M | $224M |
| Total current liabilities | $12M | $16M | $30M | $18M | $130M | $20M |
| Long-term debt | $10M | $9M | $4M | — | — | — |
| Total liabilities | $33M | $41M | $184M | $176M | $192M | $65M |
| Shareholders' equity | -$106M | $396M | $303M | $185M | $161M | $159M |
| Net debt | -$18M | -$48M | -$81M | -$47M | -$58M | -$62M |
Cash flow
Fiscal years, from Century Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$41M | -$89M | $14M | -$88M | -$110M | -$104M |
| Capital spending | $10M | $45M | $31M | $14M | $154,000 | $848,000 |
| Free cash flow | -$51M | -$134M | -$17M | -$102M | -$110M | -$105M |
| Stock-based compensation | $876,000 | $5M | $11M | $15M | $13M | $7M |
| Net borrowing | — | — | — | -$10M | — | — |
| Free cash flow margin | — | — | -318.4% | -4567.5% | -1673.8% | -95.9% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IPSC.
Open IPSC in InvestinglyQuestions
What was Century Therapeutics's revenue in 2025?
$109M in fiscal 2025, from its 10-K filing.
How much free cash flow does Century Therapeutics generate?
-$105M in fiscal 2025 (operating cash flow minus capital spending).
From Century Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.